Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress

Expert Opinion on Investigational Drugs

Volumn 17, Issue 6, 2008, Pages 855-864

  Gur, Serap ^a   Sikka, Suresh C ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Ageing; cGMP; Diabetes; Erectile dysfunction; PDE5 enzymes; PDE5 inhibitors

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; APOCYNIN; AVANAFIL; BENZAMIDE DERIVATIVE; FR 226807; GLYCERYL TRINITRATE; GUANOSINE TRIPHOSPHATE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOQUINOLINE DERIVATIVE; M VIX; METHYL 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINE CARBOXYLATE SULFATE; MIRODENAFIL; NITROUS OXIDE; PEROXYNITRITE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEIN KINASE C; PYRIMIDINE DERIVATIVE; SILDENAFIL; SILDENAFIL NITRATE; SK 3530; SLX 2101; SUPEROXIDE DISMUTASE; TA 1790; TADALAFIL; UDENAFIL; UNINDEXED DRUG; VARDENAFIL; VASOACTIVE AGENT;

AGING; CLINICAL TRIAL; COLOR VISION DEFECT; CORPUS CAVERNOSUM; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PROTECTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; OXYGEN TENSION; PATHOPHYSIOLOGY; PENIS ERECTION; RECOMMENDED DRUG DOSE; REFRACTORY PERIOD; REPERFUSION INJURY; RESPIRATORY DISTRESS; REVIEW; RHINITIS; SEXUAL SATISFACTION; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

AGING; ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIABETES COMPLICATIONS; DRUG EVALUATION, PRECLINICAL; ERECTILE DYSFUNCTION; HUMANS; MALE; NITRIC OXIDE; OXIDATIVE STRESS; OXYGEN; PHOSPHODIESTERASE INHIBITORS; RABBITS; RATS; REACTIVE OXYGEN SPECIES; VASODILATOR AGENTS;

EID: 45749098907     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.6.855     Document Type: Review

References (63)

1. Saenz De Tejada IS, Goldstein I, Azadzoi K, et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-30
2. Bellastella A, Esposito D, conte M, et al. Sexuality in aging male. J Endocrinol Invest 2005;28:55-60
3. Saenz De Tejada I, Moroukian P, Tessier J, et al. Trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model. Am J Physiol 1991;260:H1590-5
4. Gonzalez-Cadavid NF, Ignarro LJ, Rajfer J. Nitric oxide and the cyclic GMP system in the penis. Mol Urol 1999;3:51-9
5. Biel M, Zong X, Hofmann F. Cyclic nucleocide gated channels. Adv Second Messenger Phosphoprotein Res 1999;33:231-50
6. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Ann Rev Biochem 2007;76:481-511
7. Lohmann SM, Vaandrager AB, Smolenski A, et al. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 1997;22:307-12
8. Juilfs DM, Soderling S, Burns F, Beavo JA. Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 1999;135:67-104
9. Zeng X, Keyser B, Li M, Sikka SC. T-type (alpha 1G) low voltage-activated calcium channel interactions with nitric oxide-cyclic guanosine monophosphate pathway and regulation of calcium homeostasis in human cavernosal cells. J Sex Med 2005;2:620-30
10. Kim N, Vardi Y, Padma-Nathan H, et al. Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. Clin Invest 1993;91:437-42
11. De Young L, Yu D, Freeman D, et al. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003; 15:347-54
12. Gonzalez-Cadavid NF, Rajfer J. Molecular pathophysiology and gene therapy of aging-relaced erectile dysfunction. Exp Gerontol 2004;39:1705-12
13. Ferrini M, Magee TR, Verner D, et al. Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis. Biol Reprod 2001;64:974-82
14. 2* and improves erectile function in aged rats. Am J Physiol 2003;284:H1408-21
15. Fedele D, Bortolotti A, Goscelli C, et al. Erectile dysfunction among type I and type 2 diabetic in Italy. Int J Epidemiol 2000;29:524-31
16. Cartledge JJ, Eardley I, Morrison JF, Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 2001;87:394-401
17. Christ GJ, Stone B, Melman A. Age-dependent alterations in the efficacy of phenylephrine-induced contractions in vascular smooth muscle isolated from the corpus cavernosum of impotent men. Can J Physiol Pharmacol 1991;69:909-13
18. Wespes E. Smooth muscle pathology and erectile dysfunction. Int J Impot Res 2002;14:S17-21
19. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
20. Lin CS, Lau A, Tu R, et al. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 2000;268:628-35
21. Andersson KE, Hedlund P. New directions for erectile dysfunction therapies. Int J Impot Res 2002; 14:S82-92
22. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, et al. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA done. J Biol Chem 1993;268:22863-73
23. Thomas MK, Francis SH, Corbin JD. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 1990;265:14964-70
24. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, et al. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 2003;22:469-78
25. Corbin JD, Thomas MK, Wolfe L, et al. New insights into cGMP action. Adv Second Messenger Phosphoprotein Res 1990;24:411-8
26. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Ann Rev Pharmacol Toxicol 1996;36:403-27
27. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol 2004;27:120-5
28. Turko, IV,' Francis SH, Corbin JD. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. Biochemistry 1998;37:4200-5
29. Montorsi F, Briganti A, Salonia A, et al. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur Urol 2006;49:979-86
30. Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 2002;53:S45-52
31. Boulton AJM, Selam JL, Sweeney M, et al. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001;44:1296-301
32. Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. J Am Med Assoc 1999;281:421-6
33. Stuckey B, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003; 26:279-84
34. Hellstrom WJG, Gittelman M, Karlin G et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71
35. Brock G, Nehra A, Lipshultz U, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003;170:1278-83
36. Padma-Nathan H, McMurray JG, Pullman, et al. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. IC351 On-Demand Dosing Study Group. Int J Impot Res 2001; 13:2-9
37. Sáenz De Tejada I, Anglin G, Knight JR, et al. Effects of radalafil on erectile: dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64
38. Fonseca V, Seftel A, Denne J, et al. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004;47:1914-23
39. Briganti A, Salonia A, Gallina. A, et al. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. Nat Clin Pract Urol 2005;2:239-47
40. Blount MA, Zoraghi R, Ke H, et al. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase 5 dimerization. Mol Pharmacol 2006;70:1822-31
41. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92:9M-18M
42. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005;96:257-80
43. Vitezic D, Pelcic JM. Erectile dysfunction: oral pharmacotherapy options. Int J Clin Pharmacol Ther 2002;40:393-403
44. Ahn GJ, Yu JY, Choi SM, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005;28:260-6
45. Koupparis AJ, Jeremy JY, Muzaffar S, et al. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 2005;96:423-7
46. Jeremy JY, Jones RA, Koupparis AJ, et al. Reactive oxygen species and erectile dysfunction: possible role of NADPH oxidase. Int J Impot Res 2007; 19:265-80
47. Hayashi T, Juliet PA, Kano-Hayashi H, et al. NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and -independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction. Diabetes Obes Metab 2005;7:334-43
48. Muzaffar S, Shukla N, Srivastava A, et al. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 2005;146:109-17
49. Salloum FN, Ockaili RA, Wittkamp M, et al. Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mirochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol 2006;40:405-11
50. Omori K, Mochida H, Fujishige K, et al. Avanafil has the potential for the treatment of erectile dysfunction with selective phosphodiesterase-5. J Sex Med 2006;3(Suppl 3):221-2
51. Peterson C, Swearingen D. Pharmacokinetics of avanafil, a new PDE5 inhibitor being developed for erectile dysfunction. J Sex Med 2006;3(Suppl 3):253-4
52. Hatzimouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008;68:231-50
53. Kim JJ, Choi HK Lee SW, et al. A phase III study to evaluate the efficacy and safety of udenafil in Korean ED patients [abstract no. P-05-49]. J Sex Med 2006;3(Suppl 3):255
54. Kim JJ, Yang DY, Lee CH, et al. Efficacy and safety of fixed-dose udenafil (Zydena) in men with diabetes and erectile dysfunction [abstract]. J Sex Med 2008;5(Suppl 2):63
55. Prince WT, Campbell AS, Tong W, et al. SLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Sex Med 2006;3(Suppl 1): 29-30
56. Sweetnam P, Campbell S, Georgan M, et al. SLx-2101, a novel long-lasting phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction: in vivo and in vitro studies. J Sex Med 2006;3(Suppl 1):29-30
57. Paick JS, Choi HK, Kim SC, et al. Efficacy and safety of oral SK3530 in the treatment of men in Korea with erectile dysfunction: a multicenter, randomized, double blind, placebo-controlled, fixed dose, parallel group clinical trial [abstract no. OR-032]. J Sex Med 2006;3(Suppl 5):393
58. Hosogai N, Hamada K, Tomita M, et al. FR226807: a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol 200 1;428:295-302
59. Mahajan H, Richards SM, Rattigan S, et al. T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo. Br J Pharmacol 2003;140:1283-91
60. Hirose R, Okumura H, Yoshimatsu A, et al. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. Eur J Pharmacol 2001;431:17-24
61. Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-82
62. Qiu Y, Bhattacharjee S, Kraft P, et al. JNJ-10280205 and JNJ-10287069: novel PDE5 inhibitors as clinical candidates for erectile dysfunction. Int J Impot Res 2006;18:477-83
63. Shukla N, Jones R, Persad R, et al. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 2005;517:224-31